| Organizational Governance |
|
- 【Integrated Report 2025】
- Aiming to Become a "Global Specialized Player"（P3）
- Message from the President（P8）
- Sumitomo Pharma’s Value Creation Process（P22）
- Corporate Governance（P31）
|
| Human Rights |
1. Due diligence |
|
| 2. Human rights risk situations |
| 3. Avoidance of complicity |
| 4. Resolving grievances |
|
| 5. Discrimination and vulnerable groups |
|
| 6. Civil and political rights |
| 7. Economic, social and cultural rights |
| 8. Fundamental principles and rights at work |
|
| Labour Practices |
1. Employment and employment relationships |
|
| 2. Conditions of work and social protection |
| 3. Social dialogue |
|
| 4. Health and safety at work |
|
| 5. Human development and training in the workplace |
|
| The Environment Management |
1. Prevention of pollution |
|
| 2. Sustainable resource use |
| 3. Climate change mitigation and adaptation |
| 4. Protection of the environment, biodiversity and restoration of natural habitats |
|
| Fair Operating Practices |
1. Anti-corruption |
|
| 2. Responsible political involvement |
|
| 3. Fair competition |
|
| 4. Promoting social responsibility in the value chain |
|
| 5. Respect for property rights |
|
| Consumer Issues |
1. Fair marketing, factual and unbiased information and fair contractual practice |
|
| 2. Protecting consumers' health and safety |
|
| 3. Sustainable consumption |
|
| 4. Consumer service, support, and complaint and dispute resolution |
|
| 5. Consumer data protection and privacy |
|
| 6. Access to essential services |
|
| 7. Education and awareness |
|
| Community Involvement and Development |
1. Community involvement |
|
| 2. Education and culture |
|
| 3. Employment creation and skills development |
|
| 4. Technology development and access |
|
| 5. Wealth and income creation |
|
| 6. Health |
|
| 7. Social investment |